Literature DB >> 16417594

Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.

R Bhidayasiri1, F Cardoso, D D Truong.   

Abstract

Amongst all regions of the body, the craniocervical region is the one most frequently affected by dystonia. Whilst blepharospasm--involuntary bilateral eye closure--is produced by spasmodic contractions of the orbicularis oculi muscles, oromandibular dystonia may cause jaw closure with trismus and bruxism, or involuntary jaw opening or deviation, interfering with speaking and chewing. Both forms of dystonia can be effectively treated with botulinum toxin injection. This article summarizes injection techniques in both forms of dystonia and compares doses, potency and efficacy of different commercially available toxins, including Botox, Dysport, Xeomin and Myobloc/NeuroBloc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417594     DOI: 10.1111/j.1468-1331.2006.01441.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  22 in total

Review 1.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

Review 2.  [Botulinum toxin treatment in the head and neck region: current aspects, developments, and problems].

Authors:  R Laskawi
Journal:  HNO       Date:  2007-06       Impact factor: 1.284

Review 3.  Meige syndrome: what's in a name?

Authors:  Mark S LeDoux
Journal:  Parkinsonism Relat Disord       Date:  2009-05-19       Impact factor: 4.891

4.  Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report.

Authors:  Andrea Santamato; Francesco Panza; Daniela Di Venere; Vincenzo Solfrizzi; Vincenza Frisardi; Maurizio Ranieri; Pietro Fiore
Journal:  J Chiropr Med       Date:  2010-09

5.  Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis.

Authors:  Pariessa D Dadgardoust; Raymond L Rosales; Ria Monica Asuncion; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2019-01-02       Impact factor: 3.575

6.  Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia.

Authors:  Laura M Scorr; Michael R Silver; John Hanfelt; Elaine Sperin; Alan Freeman; H A Jinnah; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 7.  Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.

Authors:  Wilhelm J Schulte-Mattler
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Experience with long-term treatment with albumin-supplemented botulinum toxin type A.

Authors:  Bahram Mohammadi; Katja Kollewe; Maresa Wegener; Hans Bigalke; Reinhard Dengler
Journal:  J Neural Transm (Vienna)       Date:  2009-03-25       Impact factor: 3.575

9.  Botulinum toxin in the management of dystonia.

Authors:  Omar D Cardona-Garcia; Donald S Higgins; Eric S Molho
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

10.  Treatment of focal dystonia.

Authors:  Amit Batla; Maria Stamelou; Kailash P Bhatia
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.